Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Despite the success of KRAS G12C inhibitors in non–small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to cotarget RAS and mTOR pathways; however, toxicity due to broad mTOR inhibition has limited its utility. Therefore, we sought to develop a more...

Descripción completa

Detalles Bibliográficos
Autores principales: Nardi, Francesca, Perurena, Naiara, Schade, Amy E., Li, Ze-Hua, Ngo, Kenneth, Ivanova, Elena V., Saldanha, Aisha, Li, Chendi, Gokhale, Prafulla C., Hata, Aaron N., Barbie, David A., Paweletz, Cloud P., Jänne, Pasi A., Cichowski, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425214/
https://www.ncbi.nlm.nih.gov/pubmed/37384411
http://dx.doi.org/10.1172/JCI167651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425214/
https://www.ncbi.nlm.nih.gov/pubmed/37384411
http://dx.doi.org/10.1172/JCI167651

Ejemplares similares